Código QR (código de barras bidimensional)

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ICH. The aim of this study was to provide real-w...

תיאור מלא

שמור ב:
Principais autores: Nils Kuklik, Anika Hüsing, Andreas Stang, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Hans-Christoph Diener
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2023-07-01
סדרה:Frontiers in Neurology
נושאים:
intracranial hemorrhage
anticoagulation
dabigatran
idarucizumab
vitamin-K-antagonists
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fneur.2023.1212495/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים